[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrectomy-for-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrectomy-for-gastric-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,64,95,143,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100633367","ai-assisted-decision-making-of-reoperation-for-postoperative-bleeding-of-gastric-cancer-100633367",false,"NCT07525765","AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer","A Multicenter Observational Study to Develop and Validate a Deep Learning Model for Dynamic Assessment of Postoperative Bleeding Risk to Assist Re-operation Decision-Making in Patients With Gastric Cancer","Inclusion Criteria:\n\n1. Age: Patients aged ≥ 18 years.\n2. Diagnosis: Histologically confirmed primary gastric cancer.\n3. Surgical Procedure: Underwent radical gastrectomy (including proximal, distal, or total gastrectomy).\n4. Consent: Provision of written informed consent (required specifically for the prospective phase).\n5. Data Completeness: Availability of complete preoperative clinical data and postoperative follow-up records covering at least the first 15 days post-surgery.\n6. Oncological History: No history of other primary malignant tumors.\n\nExclusion Criteria:\n\n1. Surgical Type: Patients who underwent non-radical resection or emergency surgery.\n2. Data Quality: Missing rate of key data fields exceeds 20%.\n3. Preoperative Condition: Presence of severe preoperative infection or organ failure.\n4. Follow-up Compliance: Unwillingness to participate in prospective follow-up or inability to complete the follow-up schedule (applicable only to the prospective phase).","ALL","18 Years","90 Years",{"count":20,"type":21},7000,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this observational study is to develop and validate a deep learning model to dynamically assess postoperative bleeding risk and assist in decision-making for re-operation in adult patients (≥18 years) diagnosed with primary gastric cancer undergoing radical gastrectomy. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nCan an AI model based on perioperative dynamic physiological parameters and precise intraoperative blood loss accurately predict the risk of postoperative bleeding requiring re-operation? Does the application of this AI model improve clinical decision-making (e.g., earlier warning time, optimal intervention timing) and patient outcomes (e.g., mortality, length of stay)? Since there is no comparison group (this is a pure observational study without intervention arms), researchers will not compare different treatment groups. Instead, the investigators will evaluate the model's performance (sensitivity, negative predictive value, AUC, calibration) using retrospective data for training and prospective multi-center data for external validation.\n\nParticipants will:\n\nUndergo standard radical gastrectomy and routine postoperative care as per clinical practice (no study-specific interventions).\n\nHave their perioperative data collected, including demographics, medical history, vital signs, laboratory tests (blood gas analysis), surgical details, and precise intraoperative blood loss measurements.\n\n(For prospective participants only) Provide informed consent and complete follow-up assessments up to 30 days post-surgery.",[26,27],"Gastrectomy for Gastric Cancer","Gastric Cancer","RECRUITING","2026-04-07",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":21},"2026-04-10",{"date":36,"type":21},"2028-01-31",{"name":38,"class":39},"First Affiliated Hospital of Zhejiang University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100591618","how-epigenetic-changes-in-hmlh1-connect-lab-research-with-diagnosis-in-gastric-cancer-100591618","NCT06982768","How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer","Epigenetic Mechanisms Bridging Research and Clinical Examination in hMLH1 Hypermethylated Gastric Cancer","EMBRACE-hGC","Inclusion Criteria:\n\n* Patients who underwent elective gastrectomy for Stage I-IV gastric cancer.\n* Surgery performed at the General Surgery Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS.\n* Procedures conducted between January 2017 and August 2023.\n* Only patients who have already undergone immunohistochemistry evaluation for expression of the components of the MMR complex (MLH1, PMS2, MSH2, and MSH6).\n\nExclusion Criteria:\n\n\\- Patients with missing immunohistochemistry evaluation for the expression of the components of the MMR complex (MLH1, PMS2, MSH2, and MSH6).",{"count":50,"type":21},245,"DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have been developed and have demonstrated an association with mortality and, in some cases, with cancer incidence. Accordingly, CpG promoter hypermethylation is a well-known mechanism of gene inactivation in carcinogenesis.\n\nGastric cancer has been classified in different molecular phenotypes based on genetic and epigenetic characteristics. One of these subtypes is characterized by a high grade of microsatellite instability (MSI-H). In gastric cancer, the MSI-H status is mostly caused by methylation of the hMLH1 gene promoter (between 71% and 78%), that is also considered the representative of a gastric-specific CpG island methylation pattern (CIMP). Gastric cancer with hMLH1 hypermethylation is frequently expressed in the MSI-H phenotype but also reported in the MSI-L type. Hypermethylation has been associated with advanced age, dietary habits, smoking and alcohol consumption. Moreover, other studies on GI cancer (colorectal, rectal and gastric) have associated hMLH1 hypermethylation with decreased levels of folate, vitamin C and niacin. Last, increased oxidative stress has been proposed as one of the possible initiators of cancer development and progression through epigenetic mechanism as hypermethylation. From a clinical standpoint, MSI-H gastric cancers have been associated with increased resistance to standard chemotherapy and increased immunogenicity, representing a hypothetic ideal target to immunotherapy, that has documented clinical efficacy for this subtype. However, some authors have suggested that MSI-H GCs without hMLH1 hypermethylation and GCs with hMLH1 hypermethylation could be different in terms of clinicopathologic characteristics and biological behavior. In addition, the specific role of hMLH1 hypermethylation in resistance to standard chemotherapy is unknown, as well as its potential adjunctive role in the chemoresistance of hypermethylated - but MSI-L - tumors.\n\nIdentifying risk factors for hMLH1 hypermethylated GC could have relevant implications in terms of disease prevention and even reversal of the hypermethylation mechanisms through natural as well as synthetic compounds. It could also identify a predictive tool to better stratify patients for expected sensitivity to specific chemotherapy (or biological therapy) regimens. Therefore, this preliminary study aims to determine if the development of hMLH1-methylated GC is associated with specific clinicopathologic characteristics and environmental habits. It also aims to report on the biological behavior of these tumors, as well as on their chemosensitivity to platin-based chemotherapy regimens.",[26,53,54,27],"Gastrectomy","MLH1 Gene Mutation","2025-12-29",{"date":57,"type":32},"2026-01-02",{"date":59,"type":32},"2024-09-01",{"date":61,"type":21},"2026-04-30",{"name":63,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100591786","effectiveness-of-eras-on-postoperative-recovery-after-minimally-invasive-gastrectomy-100591786","NCT06984952","Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy","Effectiveness of Enhanced Recovery After Surgery (ERAS) on Postoperative Recovery After Minimally Invasive Gastrectomy: A Multi-center Open-labeled Randomized Controlled Study","Inclusion Criteria:\n\n* Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer\n* American Society of Anesthesiologists physical status classification I to III\n* Ability to provide written informed consent, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately\n\nExclusion Criteria:\n\n* Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy)\n* History of upper abdominal surgery (except for cholecystectomy)\n* Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs\n* Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study","19 Years",{"count":73,"type":21},308,"INTERVENTIONAL",[76],"NA","This prospective, randomized, open-label, multicenter study is designed to evaluate the impact of an enhanced recovery after surgery (ERAS) protocol on the rate of meeting discharge criteria in patients undergoing minimally-invasive gastrectomy for gastric cancer. We hypothesize that implementation of our ERAS protocol will significantly increase the proportion of patients who meet standardized discharge criteria following minimally-invasive gastrectomy.",[79,26],"Enhanced Recovery After Surgery",[81,82,83,84],"enhanced recovery after surgery","stomach neoplasms","gastrectomy for gastric cancer","pain, postoperative","2025-09-04",{"date":87,"type":32},"2025-09-05",{"date":89,"type":32},"2025-06-13",{"date":91,"type":21},"2029-03-31",{"name":93,"class":39},"Seoul National University Hospital",10,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":74,"phases":106,"briefSummary":109,"conditions":110,"keywords":124,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.","80 Years",{"count":105,"type":21},150,[107,108],"PHASE2","PHASE3","The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[27,111,112,113,114,115,116,117,118,119,120,121,53,26,122,123],"Stomach Cancer","GastroEsophageal Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Gastric Neoplasm","Stomach Neoplasm","Gastrointestinal Cancer","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma","Chemotherapy","Gastric Resection","Gastric (Cardia, Body) Cancer",[125,126,127,53,128,129,130,131,132],"Total neoadjuvant chemotherapy","FLOT","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","Gastric cancer","2025-04-30",{"date":135,"type":32},"2025-05-06",{"date":137,"type":32},"2025-03-25",{"date":139,"type":21},"2032-12-31",{"name":141,"class":39},"Ukrainian Society of Clinical Oncology",2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":74,"phases":153,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":142},"100574151","phase-3-investigation-of-impact-of-indocyanine-green-on-volume-of-lymphadenectomy-in-resectable-gastric-cancer-100574151","NCT06755554","Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer","Investigation of Effect of Indocyanine Green on Volume of Lymph Node Dissection in Surgical Treatment of Gastric Cancer","ICGastr","Inclusion Criteria:\n\n* Tumor spread: cT2-4a cN0-3,\n* cM0;\n* Age: 18 - 80;\n* Gender: men and women;\n* ECOG: 0 - 1;\n* Histologic type of tumor: Adenocarcinoma of any subtype;\n* Degree of differentiation: G1 - G4;\n* Tumor localization: cardiac region, stomach floor, stomach body, antrum, pylorus, and pyloric region of the stomach;\n* Tumor spread: absence of tumor invasion into adjacent structures;\n* No history of cancer in the last 5 years;\n* No previous chemotherapy, surgery or radiation treatment for another cancer (except for neoadjuvant chemotherapy for gastric cancer);\n* Absence of severe comorbidity restricting laparoscopic approach.\n\nExclusion Criteria:\n\n* M1 (distant metastases);\n* ECOG 2 - 4;\n* Age over 80 and under 18;\n* Presence of severe comorbidities, ASA\\> 3;\n* Patient refusal to participate in the study.",{"count":152,"type":21},105,[108],"The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph nodes; the number of postoperative complications and complications associated with the administration of ICG.\n\nPatients who meet the inclusion criteria for this study will be enrolled in the study after reviewing and signing an informed consent form.\n\nAll patients will be included in one group and will receive surgical treatment in the amount of total or subtotal gastrectomy with lymphadenectomy D1, D1+, D2 or D2+.\n\nICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.\n\nAssessment of the number of fluorescent lymph nodes will be performed intraoperatively with their subsequent removal and mapping. The incidence of postoperative complications will be assessed by Clavien-Dindo.",[156,157,27,26],"Gastric Cancer Stage II","Gastric Cancer Stage III",[159,160,161],"indocyanine green","gastric cancer","gastrectomy",{"date":163,"type":32},"2025-03-30",{"date":165,"type":32},"2025-01-01",{"date":167,"type":21},"2026-02-01",{"name":141,"class":39},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":179,"conditions":180,"keywords":188,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100551962","evaluation-of-intra-operative-photographs-for-the-assessment-of-a-proper-lymphadenectomy-in-minimally-invasive-gastrectomies-for-gastric-cancer-photonodes-100551962","NCT06466902","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastric Cancer Surgery (PhotoNodes)","PhotoNodes","Inclusion Criteria:\n\n* All patients undergoing minimally invasive curative-intent surgery for gastric adenocarcinoma with D2 lymphadenectomy\n* Patients undergoing upfront surgery or treated with a neoadjuvant\u002Fperioperative chemotherapy\n* Total or Subtotal Gastrectomy\n* Laparoscopic or Robotic approach\n\nExclusion Criteria:\n\n* Age less than 18 year old\n* Esophago-gastric junction cancer Siewert type I, II or III\n* Metastatic disease\n* Lymphadenectomy less than D2\n* Open surgery\n* Conversion to open surgery\n* Palliative gastrectomy\n* R1 or R2 resection\n* Multivisceral resection except for cholecystectomy\n* Surgical procedures other than subtotal or total gastrectomy\n* A single node station rated as unevaluable by more than one reviewer",{"count":178,"type":21},326,"Even after the wide introduction of chemo\u002Fradiotherapy in the treatment algorithm, adequate surgery remains the cornerstone of gastric cancer treatment with curative intent. A proper D2 lymphadenectomy is associated with improved cancer specific survival as confirmed in Western countries by fifteen-year follow-up results of Dutch and Italian randomized trials.\n\nIn clinical practice, the total number of harvested lymph nodes is often considered as a surrogate marker for adequate D2 lymphadenectomy; nonetheless, the number of retrieved nodes does not necessarily correlate with residual nodes, which intuitively could represent a more reliable marker of surgical adequacy. The availability of an efficient tool for evaluating the absence of residual nodes in the operative field at the end of node dissection could better correlate with survival outcomes.\n\nThe goal of this multicentric observational prospective study is to test the reliability of a new score (PhotoNodes Score) created to rate the quality of the lymphadenectomy performed during minimally invasive gastrectomy for gastric cancer. The score is assigned by assessing the absence of residual nodes at the end of node dissection on a set of laparoscopic\u002Frobotic high quality intraoperative images collected from each patient undergoing a minimally invasive gastrectomy with D2 node dissection.\n\nIdeally, this tool could be a new indicator of the quality of D2 dissection and could assume a prognostic role in the treatment of gastric cancer.",[27,113,181,182,26,183,184,185,186,187],"Lymphadenectomy","Minimally Invasive Surgery","Laparoscopic Surgery","Robotic Surgery","Survival Outcomes","Survival Analysis","Quality Of Care",[189,190],"D2 Lymphadenectomy quality assessment","Minimally invasive gastric cancer oncologic surgery","2024-07-03",{"date":193,"type":32},"2024-07-05",{"date":195,"type":32},"2022-12-22",{"date":197,"type":21},"2027-12",{"name":199,"class":39},"Azienda Ospedaliero-Universitaria di Parma",8]